Alfonso Sánchez-Muñoz

Summary

Affiliation: Hospital Universitario
Country: Spain

Publications

  1. doi request reprint Cisplatin-based radiochemotherapy improves the negative prognosis of c-erbB-2 overexpressing advanced cervical cancer
    José Pérez-Regadera
    Servicio de Oncologia Radioterapica, Hospital Universitario Doce de Octubre, Avenida de Córdoba Km 5 4, 28041 Madrid, Spain
    Int J Gynecol Cancer 20:164-72. 2010
  2. doi request reprint Outcome of small invasive breast cancer with no axillary lymph node involvement
    Alfonso Sánchez-Muñoz
    Service of Medical Oncology, Virgen de la Victoria University Hospital, Malaga, Spain Service of Medical Oncology, Serranía de Ronda Hospital, Malaga, Spain
    Breast J 17:32-8. 2011
  3. ncbi request reprint Tumor histological subtyping determined by hormone receptors and HER2 status defines different pathological complete response and outcome to dose-dense neoadjuvant chemotherapy in breast cancer patients
    A Sánchez-Muñoz
    Medical Oncology Service, Hospital Universitario Virgen de la Victoria, Campus Teatinos s n, 29010, Malaga, Spain
    Clin Transl Oncol 16:548-54. 2014
  4. pmc Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer
    Alfonso Sánchez-Muñoz
    Servicio de Oncologia Medica, Hospital Universitario Virgen de Victoria, Campus de Teatinos s n, 29010 Malaga, Spain
    BMC Cancer 10:136. 2010
  5. doi request reprint The role of immunohistochemistry in breast cancer patients treated with neoadjuvant chemotherapy: an old tool with an enduring prognostic value
    Alfonso Sánchez-Muñoz
    Medical Oncology Service, Hospital Universitario Virgen de la Victoria de Málaga, Malaga, Spain
    Clin Breast Cancer 13:146-52. 2013
  6. doi request reprint Targeted therapies in the treatment of germ cell tumors: the need for new approaches against "orphan" tumors
    Alfonso Sánchez-Muñoz
    Medical Oncology Service, Hospital Universitario Virgen de la Victoria of Málaga, Spain
    Crit Rev Oncol Hematol 83:444-51. 2012
  7. doi request reprint Male breast cancer: immunohistochemical subtypes and clinical outcome characterization
    Alfonso Sánchez-Muñoz
    Medical Oncology Service, Hospital Universitario Virgen de la Victoria, Malaga, Spain
    Oncology 83:228-33. 2012
  8. doi request reprint Negative prognostic impact of the coexpression of epidermal growth factor receptor and c-erbB-2 in locally advanced cervical cancer
    José Pérez-Regadera
    Department of Radiation Oncology, Hospital Universitario Doce de Octubre, Madrid, Spain
    Oncology 76:133-41. 2009
  9. doi request reprint Limited impact of palliative chemotherapy on survival in advanced solid tumours in patients with poor performance status
    Alfonso Sánchez-Muñoz
    Medical Oncology Department, Hospital Universitario Virgen de la Victoria, Malaga, Spain
    Clin Transl Oncol 13:426-9. 2011
  10. doi request reprint Bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer
    Alfonso Sánchez-Muñoz
    Servicio de Oncologia Medica, Hospital Universitario Virgen de la Victoria, Malaga, Espana
    Oncology 79:98-104. 2010

Collaborators

Detail Information

Publications22

  1. doi request reprint Cisplatin-based radiochemotherapy improves the negative prognosis of c-erbB-2 overexpressing advanced cervical cancer
    José Pérez-Regadera
    Servicio de Oncologia Radioterapica, Hospital Universitario Doce de Octubre, Avenida de Córdoba Km 5 4, 28041 Madrid, Spain
    Int J Gynecol Cancer 20:164-72. 2010
    ..To determine the impact of c-erb-B2 overexpression on disease-free survival (DFS) and local relapse in patients with advanced cervical cancer (CC) receiving concurrent chemoradiotherapy treatment...
  2. doi request reprint Outcome of small invasive breast cancer with no axillary lymph node involvement
    Alfonso Sánchez-Muñoz
    Service of Medical Oncology, Virgen de la Victoria University Hospital, Malaga, Spain Service of Medical Oncology, Serranía de Ronda Hospital, Malaga, Spain
    Breast J 17:32-8. 2011
    ..07). The prognosis of our pT1≤1cm N0M0 tumors was excellent, although the absence of systemic adjuvant therapy in one-half of the patients...
  3. ncbi request reprint Tumor histological subtyping determined by hormone receptors and HER2 status defines different pathological complete response and outcome to dose-dense neoadjuvant chemotherapy in breast cancer patients
    A Sánchez-Muñoz
    Medical Oncology Service, Hospital Universitario Virgen de la Victoria, Campus Teatinos s n, 29010, Malaga, Spain
    Clin Transl Oncol 16:548-54. 2014
    ....
  4. pmc Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer
    Alfonso Sánchez-Muñoz
    Servicio de Oncologia Medica, Hospital Universitario Virgen de Victoria, Campus de Teatinos s n, 29010 Malaga, Spain
    BMC Cancer 10:136. 2010
    ..We aimed to study the mutation frequency of KRAS in that subtype of breast tumors to provide a molecular basis for the evaluation of anti-EGFR therapies...
  5. doi request reprint The role of immunohistochemistry in breast cancer patients treated with neoadjuvant chemotherapy: an old tool with an enduring prognostic value
    Alfonso Sánchez-Muñoz
    Medical Oncology Service, Hospital Universitario Virgen de la Victoria de Málaga, Malaga, Spain
    Clin Breast Cancer 13:146-52. 2013
    ....
  6. doi request reprint Targeted therapies in the treatment of germ cell tumors: the need for new approaches against "orphan" tumors
    Alfonso Sánchez-Muñoz
    Medical Oncology Service, Hospital Universitario Virgen de la Victoria of Málaga, Spain
    Crit Rev Oncol Hematol 83:444-51. 2012
    ..In this article, we review some of the new targeted biologic therapies that act on the most relevant oncogenesis pathways and are in clinical development for the treatment of GCTs...
  7. doi request reprint Male breast cancer: immunohistochemical subtypes and clinical outcome characterization
    Alfonso Sánchez-Muñoz
    Medical Oncology Service, Hospital Universitario Virgen de la Victoria, Malaga, Spain
    Oncology 83:228-33. 2012
    ..The aim of this study was to assess the molecular subtype profiles of male breast cancer (MBC) and subsequent clinical outcome using a validated 6-marker immunohistochemical panel...
  8. doi request reprint Negative prognostic impact of the coexpression of epidermal growth factor receptor and c-erbB-2 in locally advanced cervical cancer
    José Pérez-Regadera
    Department of Radiation Oncology, Hospital Universitario Doce de Octubre, Madrid, Spain
    Oncology 76:133-41. 2009
    ....
  9. doi request reprint Limited impact of palliative chemotherapy on survival in advanced solid tumours in patients with poor performance status
    Alfonso Sánchez-Muñoz
    Medical Oncology Department, Hospital Universitario Virgen de la Victoria, Malaga, Spain
    Clin Transl Oncol 13:426-9. 2011
    ..This study is intended to assess the impact on overall survival of palliative chemotherapy in patients with AST and admitted to hospital as a result of their poor ECOG status...
  10. doi request reprint Bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer
    Alfonso Sánchez-Muñoz
    Servicio de Oncologia Medica, Hospital Universitario Virgen de la Victoria, Malaga, Espana
    Oncology 79:98-104. 2010
    ..To retrospectively assess the efficacy and safety of bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer...
  11. doi request reprint Impact of epidermal growth factor receptor expression on disease-free survival and rate of pelvic relapse in patients with advanced cancer of the cervix treated with chemoradiotherapy
    José Pérez-Regadera
    Department of Radiation Oncology, Hospital Universitario Doce de Octubre, Madrid, Spain
    Am J Clin Oncol 34:395-400. 2011
    ..To determine the impact of the expression of epidermal growth factor receptor (EGFR) on disease-free survival (DFS) and on pelvic relapse in patients with advanced cancer of the cervix receiving concurrent chemoradiotherapy...
  12. doi request reprint Is it possible to increase pCR in the neoadjuvant treatment with a dose-dense/sequential combination?: results from a phase II Trial combining epirubicin and cyclophosphamide followed by paclitaxel and gemcitabine ± trastuzumab in stage II and III breast
    Alfonso Sánchez-Muñoz
    Department of Oncology, Complejo Hospitalario de Jaen, Spain
    Am J Clin Oncol 33:432-7. 2010
    ..Secondary endpoints: clinical response rate, disease free survival, safety and correlation between pCR and biologic markers...
  13. ncbi request reprint Tumour molecular subtyping according to hormone receptors and HER2 status defines different pathological complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer
    Alfonso Sánchez-Muñoz
    Department of Oncology, Complejo Hospitalario de Jaen, Jaen, Spain
    Clin Transl Oncol 10:646-53. 2008
    ..To study the role of breast cancer molecular subtypes according to hormone receptors and HER2 status as a predictive factor for pathological complete response (pCR) to neoadjuvant chemotherapy...
  14. ncbi request reprint Targeted therapy of metastatic breast cancer
    Alfonso Sánchez-Muñoz
    Medical Oncology Department, Hospital Clinico Universitario Virgen de la Victoria, Malaga, Spain
    Clin Transl Oncol 11:643-50. 2009
    ....
  15. ncbi request reprint Current status of anti-angiogenic agents in the treatment of ovarian carcinoma
    Alfonso Sánchez-Muñoz
    Medical Oncology Department, Hospital Clinico Universitario Virgen de la Victoria, Malaga, Spain
    Clin Transl Oncol 11:589-95. 2009
    ....
  16. ncbi request reprint Gonadotropin and steroid receptors as prognostic factors in advanced ovarian cancer: a retrospective study
    Lorenzo Alonso
    Medical Oncology Service, Hospital Universitario Virgen de la Victoria, Malaga, Spain
    Clin Transl Oncol 11:748-52. 2009
    ..Also patients with the same histology achieve different outcomes in terms of survival. We decided to study gonadotropin and steroid receptors and to consider if these histological markers could select patients with different prognosis...
  17. doi request reprint Serum protein levels following surgery in breast cancer patients: a protein microarray approach
    Luís G Pérez-Rivas
    Department of Medical Oncology, Hospital Universitario Virgen de la Victoria, Campus de Teatinos s n, 29010 Malaga, Spain
    Int J Oncol 41:2200-6. 2012
    ..In conclusion, breast surgery induced distinct changes in the concentrations and dynamics of serum proteins in invasive breast cancer patients compared with healthy women and non-invasive tumor patients...
  18. ncbi request reprint Optimal adjuvant hormonal therapy in postmenopausal women with hormone-receptor-positive early breast cancer: have we answered the question?
    Alfonso Sánchez-Muñoz
    Medical Oncology Department, Hospital Universitario Virgen de Victoria, Malaga, Spain
    Clin Transl Oncol 12:614-20. 2010
    ..Available data in support of and against each strategy is evaluated. The safety profiles of tamoxifen and aromatase inhibitors is also examined...
  19. ncbi request reprint [Medical errors in oncology and patient safety]
    Lorenzo Alonso-Carrión
    Servicio de Oncologia Medica, Hospital Clinico Universitario de Malaga, Spain
    Med Clin (Barc) 126:779-81. 2006
  20. ncbi request reprint [Woman with a history of cancer and pain in the right thigh: an infection spread by contiguity]
    Francisco López-Medrano
    Unidad de Enfermedades Infecciosas, Hospital Universitario 12 de Octubre, Madrid, Espana
    Enferm Infecc Microbiol Clin 24:129-30. 2006
  21. ncbi request reprint Assessment of procalcitonin as a diagnostic and prognostic marker in patients with solid tumors and febrile neutropenia
    Antonio Jimeno
    Division of Medical Oncology, University Hospital 12 de Octubre, Madrid, Spain
    Cancer 100:2462-9. 2004
    ..The current study prospectively evaluated the efficacy of baseline procalcitonin (PCT) in the detection of bacteremia and in the prediction of outcome in patients with solid tumors and febrile neutropenia...
  22. doi request reprint Risk-adapted treatment in clinical stage I testicular seminoma: the third Spanish Germ Cell Cancer Group study
    Jorge Aparicio
    Hospital Universitario y Politécnico La Fe, Valencia, Spain
    J Clin Oncol 29:4677-81. 2011
    ..The aim was to reduce both the risk of relapse and the proportion of patients receiving adjuvant chemotherapy while maintaining a high cure rate...